Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lennox-Gastaut syndrome

- PMLiVE

Takeda starts trial of norovirus vaccine

If approved the drug is anticipated to surpass sales of GSK’s Rotarix vaccine

- PMLiVE

Takeda forms new women’s health and cancer company

Recruits former Medivation CMO Lynn Seely to lead Myovant Sciences

Takeda appoints chief financial officer and corporate officer

James Kehoe takes on both roles from 15 June

UK Life Sciences Strategy - one year on

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Collaboration aims to establish comprehensive database to accelerate drug development

- PMLiVE

Teva and Takeda appoint head of Japanese generics venture

Hiroshi Matsumori will lead partnership of Teva’s generics portfolio and Takeda brands

- PMLiVE

3D printed epilepsy drug launched in the US

Aprecia’s Spritam is now available as a prescription drug

- PMLiVE

GW ascendant as epilepsy drug clears phase III trial

Epidiolex proves effective in controlling seizures in children with Dravet syndrome

- PMLiVE

UCB bags FDA approval for epilepsy drug Briviact

Wins US licence as the add-on treatment is launched in Germany and the UK

- PMLiVE

Forging a path in specialty care

Takeda’s Marc Princen on the company’s plans to build a reputation in oncology, gastroenterology and vaccine

- PMLiVE

UCB wins European approval for epilepsy drug Briviact

Plans first launches within weeks

China flag thumb

AstraZeneca sets sights on China with Takeda deal

Buys the Japanese firm's respiratory drugs to extends their ongoing biologics R&D collaboration

- PMLiVE

FDA clears Takeda’s oral multiple myeloma drug

Ninlaro is the first oral proteasome inhibitor to get a green light from the FDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links